Table 3 Relationship between expression levels of miR-498-5p and clinical and pathological features of the NSCLC individuals
Clinical Characteristics | Non-increased (ΔΔCt ≤ − 1) n = 28 | Increased (ΔΔCt > − 1) n = 32 | Test of Significance |
|---|---|---|---|
Sex | |||
Female | 13 (21.67%) | 8 (13.33%) | χ2 = 3.0141 |
Male | 15 (25.00%) | 24 (40.00%) | P = 0.0825 |
Age | |||
< 60 | 18 (30.00%) | 18 (30.00%) | χ2 = 0.4018 |
>=60 | 10 (16.67%) | 14 (23.33%) | P = 0.5262 |
Tumour Type | |||
Squamous cell lung carcinoma | 10 (16.67%) | 15 (25.00%) | |
Lung adenocarcinoma | 16 (26.67%) | 17 (28.33%) | χ2 = 2.7760 |
Others | 2 (3.33%) | 0 (0.00%) | P = 0.3037 F |
T Stage | |||
T1 | 8 (13.33%) | 19 (31.67%) | χ2 = 5.7251 |
T2 + T3 | 20 (33.33%) | 13 (21.67%) | P = 0.0167 |
N Stage | |||
N0 | 9 (15.00%) | 22 (36.66%) | χ2 = 8.0137 |
N1 + N2 | 19 (31.67%) | 10 (16.67%) | P = 0.0046 |
Tumour Grade | |||
I + II | 13 (21.67%) | 26 (43.33%) | χ2 = 7.9592 |
III + IV | 15 (25.00%) | 6 (10.00%) | P = 0.0048 |
Differentiation | |||
Well | 7 (11.67%) | 7 (11.67%) | |
Moderate | 15 (25.00%) | 18 (30.00%) | χ2 = 0.0834 |
Poor | 6 (10.00%) | 7 (11.67%) | P = 0.9592 |